Pancreatic cancer · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Gemcitabine, Cetuximab, RT Variant #01 | — | R 132 682 | 42d | — | — | ~1 | ~R 132 682 indirect | — |
Docetaxel, Gemcitabine, RT Variant #01 | — | R 14 207 | 14d | — | — | ~3 | ~R 42 622 indirect | — |
Gemcitabine and RT Variant #01 | — | R 8 361 | 28d | — | 15.7 mo | 1 | R 8 361 PFS proxy | 2 |
FOLFIRINOX/modified FOLFIRINOX +/- Chemoradiation Variant #01 | — | R 5 545 | 14d | — | — | ~8 | ~R 44 362 indirect | — |
mFOLFIRINOX Variant #04 | — | R 3 444 | 14d | 9.7 mo | — | 2 | R 6 887 PFS proxy | 1 |
mFOLFIRINOX (no folinic acid) Variant #01 | — | R 3 200 | 14d | — | — | ~8 | ~R 25 600 indirect | — |
6 of 6 regimens shown